General Description
White to pale cream-colored crystalline powder. Odorless or almost odorless. Tasteless. Sublimes without decomposition at 410°F.
Reactivity Profile
GRISEOFULVIN(126-07-8) is incompatible with strong oxidizing agents. .
Air & Water Reactions
Insoluble in water.
Hazard
Possible carcinogen.
Fire Hazard
Flash point data for this chemical are not available. GRISEOFULVIN is probably combustible.
Description
Griseofulvin (126-07-8) is an antifungal antimitotic agent. Induces apoptosis of human germ cell tumor cells via disruption of connexin 43/tubulin association concomitant with enhanced translocation of connexin 43 from the cytoplasm to the nucleus.1?Inhibits the growth of adrenocortical cancer cells?in vitro.2 Griseofulvin inhibits centrosome clustering, induces spindle multipolarity, mitotic arrest and cell death in multiple tumor cell lines but not in diploid fibroblasts and keratinocytes with normal centrosome content.3
Originator
Grifulvin,McNeil,US,1959
Uses
adrenegic blocker, Ca channel blocker, coronary vasodilator, antiarrhythmic
Uses
An antifungal and antiproliferative agent that affects microtubules.
Uses
antifungal, inhibits mitosis in metaphase
Uses
Griseofulvin is a spirobenzofuran produced by a number of Penicillium species, first isolated in the 1930s by Raistrick's group. Griseofulvin is a selective antifungal agent used to treat skin infections in animals and humans. Griseofulvin acts by binding to fungal tubulin and inhibiting the mitotic spindle. Griseofulvin's ability to bind to keratin is considered an important aspect of the metabolite's access to dermatophytic fungi. More recently, griseofulvin has become an important phenotypic marker in Penicillium taxonomy.
Uses
It is an antifungal drug. It is used both in animal and in humans, to treat rigworm infections of the skin and nails. It is derived from the mold Penicillium griseofulvum.Environmental contaminants; Food contaminants.
Definition
ChEBI: An oxaspiro compound produced by Penicillium griseofulvum. It is used by mouth as an antifungal drug for infections involving the scalp, hair, nails and skin that do not respond to topical treatment.
Manufacturing Process
The experiment was carried out on the 1,000 gallon scale. Three impellers
1'8" diameter at 220 rpm were employed. The air rates were 0 to 5 hours, 40
cfm, 5 to 10 hours, 80 cfm and after 10 hours, 125 cfm. The inoculum rate
was 10% v/v. It was prepared by the standard inoculum development
technique on the following medium:
This was inoculated with a spore suspension of P. patulurn (1 liter containing
3-5 x 107 spores/ml) and grown at 25°C in 100 gallon tank. The inoculum is
transferred at 40 hours or when the mycelial volume (after spinning 10
minutes at 3,000 rpm) exceeds 25%. The fermentation is conducted as near
to the ideal pH curve as possible by addition of crude glucose, according to US
Patent 3,069,328.
Brand name
Fulvicin Bolus [Veterinary]
(Schering-Plough Animal Health); Fulvicin-P/G (Schering);
Fulvicin-U/F (Schering); Fulvicin-U/F Powder and
Tablets [Veterinary] (Schering-Plough Animal Health);
Grifulvin V (Ortho Pharmaceutical); Grisactin (Wyeth-
Ayerst); Gris-PEG (Allergan Herbert);B-gf;Delmofluvina;Flugolin;Fulcine-125;Fulcine-s;Fulvicin p/g;Fulvicin u/f;Fulvicina;Gefulvine;Grfulvin v;Grisaltin;Grisefalin;Grisefulvin;Griseomed;Griseostatin;Grisovina fp;Grisovine;Grisovin-fp;Grisowen;Lamoryl-novum;Lamoyl;Likuden m;Microcidal;Neo fulcin;Neo-filcin;Norofluvin;Ocufen;Sulvina.
Therapeutic Function
Antifungal
World Health Organization (WHO)
Griseofulvin, isolated from a penicillin producing mould, has
been widely used as a systemically administered antifungal agent in man for over
20 years. It is effective in dermatophyte infections (including tinea barbae and tinea
capitis) but it is inactive against yeasts and bacteria. Evidence that very high doses
of griseofulvin are carcinogenic, teratogenic and fetotoxic in laboratory animals
has led to an acceptance that it should not be used to treat trivial infections that respond to topical therapy. Oral formulations of griseofulvin are included in the
WHO Model List of Essential Drugs.
(Reference: (WHTAC1) The Use of Essential Drugs, 2nd Report of the WHO Expert
Committee, 722, , 1985)
Antimicrobial activity
The spectrum of useful activity is restricted to dermatophytes
causing skin, nail and hair infections (Epidermophyton,
Microsporum and Trichophyton spp.). Resistance has seldom
been reported.
Pharmaceutical Applications
A fermentation product of various species of Penicillium,
including Pen. griseofulvum. Available as fine-particle or ultrafine-
particle formulations for oral use.
Mechanism of action
The mechanism of action of griseofulvin is through binding to the protein tubulin, which interferes with the function of the mitotic spindle and, thereby, inhibits cell division. Griseofulvin also may interfere directly with DNA replication. Griseofulvin is gradually being replaced by newer agents .
Clinical Use
Dermatophyte infections of hair, skin and nail
Clinical Use
In the treatment of ringworm of the beard, scalp,
and other skin surfaces, 4 to 6 weeks of therapy is often
required. Therapy failure may be to the result of an incorrect
diagnosis; superficial candidiasis, which may resemble
a dermatophyte infection, does not respond to
griseofulvin treatment. Onychomycosis responds very
slowly to griseofulvin (1 year or more of treatment is
commonly required) and cure rates are poor; itraconazole
and terbinafine hydrochloride are more effective
than griseofulvin for onychomycosis.
Synthesis
Griseofulvin, 7-chloro-2,4,6-trimethoxy-6-methylspiro[benzofuran-
2(3H),1-[2]-cyclohexen]-3,4-dione (35.4.1), is an antibiotic produced by the mycelial
fungus Penicillium patulum.
Veterinary Drugs and Treatments
In veterinary species, griseofulvin is approved for use in dogs and
cats to treat dermatophytic fungal (see below) infections of the skin,
hair and claws, and to treat ringworm (caused by T. equinum and
M. gypseum) in horses. It has also been used in laboratory animals
and ruminants for the same indications. The oral tablets approved
for dogs and cats are no longer marketed in the USA, but human
dosage forms are available.
Metabolism
Griseofulvin is metabolized by the liver, and its metabolites are excreted
in the urine. It is highly protein bound and, therefore, may have high tissue
levels. However, tissue levels decrease and fall as soon as griseofulvin is
discontinued such that its presence is no longer detectable 2 to 3 days after
cessation of therapy.
Purification Methods
Crystallise it from *benzene or EtOH. Purify 2g of griseofulvin by chromatography on Alumina (40 x 1.5cm) and elute with *C6H6/MeOH (199:1) and follow the UV blue fluorescent band. [MacMillan J Chem Soc 1823 1959, Beilstein 18 III/IV 3160, 18/5 V 150.]
Dosage forms
The average treatment time for tinea capitis is 4 to 6 weeks; for tinea
corporis, 2 to 4 weeks; and for tinea pedis, 4 to 8 weeks. Because of the
low cure rate and length of therapy, griseofulvin is not commonly used for
onychomycosis of the fingernails or toenails. Complete blood count (CBC)
is monitored every 3 months during long-term therapy.
References
1) Mauro?et al. (2013),?The anti-mitotic drug griseofulvin induces apoptosis of human germ cell tumor cells through a connexin 43-dependent molecular mechanism; Apoptosis,?18?480
2) Bramann?et al. (2013),?Griseofulvin inhibits the growth of adrenocortical cancer cells in vitro; Horm. Metab. Res.,?45?297
3) Rebacz?et al. (2007),?Identification of griseofulvin as an inhibitor of centrosomal clustering in a phenotype-based screen; Cancer Res., 67?6342